Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL28890378 | 0.97 | ALDH1A1 (0.68) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL1585849 | 0.88 | — | — | |
| Imidazole SCHEMBL4200475 | 0.88 | ALDH1A1 (0.93) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL28641884 | 0.86 | ALDH1A1 (0.68) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL1767566 | 0.86 | ALDH1A1 (0.68) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL2635292 | 0.85 | — | — | |
| Imidazole SCHEMBL1331382 | 0.85 | — | — | |
| Imidazole SCHEMBL30382963 | 0.85 | — | — | |
| Imidazole SCHEMBL2684565 | 0.85 | ALDH1A1 (1.00) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL897 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018251-B2 | Method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells | CHINA MEDICAL UNIVERSITY (TW) | 2015-04-28 | — | — | US | disclosed |
| EP-2438914-B1 | Pharmaceutical composition comprising Z-butylidenephthalide for treating brain cancer or reducing temozolomide-resistance of brain cancer cells | UNIV CHINA MEDICAL (TW) | 2013-05-08 | — | — | EP | disclosed |
| US-20120178803-A1 | METHOD FOR TREATING BRAIN CANCER OR REDUCING TEMOZOLOMIDE-RESISTANCE OF BRAIN CANCER CELLS | CHINA MEDICAL UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178803-A1 | METHOD FOR TREATING BRAIN CANCER OR REDUCING TEMOZOLOMIDE-RESISTANCE OF BRAIN CANCER CELLS | MGMT, SLC11A2, GABARAPL2 | ALDH1A1 1034/4885FKBP5 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.